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parison cohort ($76 vs. $128) and remained favorable 
for capecitabine versus individual therapy subgroups
(5FULV: $75, 5FULV then CPT: $162, and 5FULV plus
CPT: $228). The total cost for chemotherapy and 
supportive care with capecitabine was much lower per
patient ($3,264 vs. $10,112). Savings with capecitabine
were primarily realized from reduced cost of chemo-
therapy ($2,416 vs. $8,499), anti-emetics ($83 vs. $999)
and anti-infective agents ($19 vs. $69) relative to 
comparison therapies.
CONCLUSION: Oral administration of capecitabine
offers similar clinical outcomes and superior cost-
effectiveness relative to comparison therapies.
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OBJECTIVES: Systemic fungal infections are becoming
increasingly common, particularly among immunocom-
promised patients. Our objective was to examine the 
clinical and economic effects of these infections.
METHODS: This study involved a retrospective cohort
analysis of the excess mortality, length of stay (LOS), and
costs attributable to serious fungal infections among 
hospitalized elderly patients with acute myeloid leukemia
(AML). Linked data from the Surveillance, Epidemiology
and End Results (SEER) Program of the National Cancer
Institute and Medicare claims data were used for the
analysis. Study cohorts included patients aged 65 years
and older who were newly diagnosed with AML between
1991 and 1996 and who developed a serious fungal 
infection (deﬁned by selected ICD-9-CM codes) during an
inpatient hospitalization (N = 80), and matched (1 :1)
hospitalized controls who did not develop a fungal 
infection. Matching variables included factors expected to
inﬂuence LOS, including age, geographic region, timing
of hospitalization, recent treatment with chemotherapy,
and presence of a concomitant bacterial infection.
RESULTS: Average age in both cohorts was 72.9 years.
Groups were similar on key non-matched characteristics,
including chronic comorbidities and metropolitan 
residence. Patients with serious fungal infections had
higher in-hospital mortality than controls (36% vs. 25%;
p = 0.12), longer LOS (mean ± SD: 31 ± 19 vs. 20 ± 15;
median: 27 vs. 16; p < 0.0001) and more ICU days (mean
± SD: 2.7 ± 7 vs. 1.9 ± 6; p = 0.22). Medicare payments
(in 1998 US dollars) also were signiﬁcantly higher among
patients with fungal infections (mean ± SD: $34,217 ±
31,821 vs. $22,547 ± 17,000 for controls; median:
$25,930 vs. $19,661; p < 0.01), with a larger difference
noted between groups when mean hospital charges were
assessed ($110,582 vs. $60,259; p < 0.0001). The rate of
rehospitalization for any reason within 30 days was
nearly identical in the 2 groups (47%).
CONCLUSIONS: The excess mortality and LOS 
attributable to serious fungal infections are substantial, a
ﬁnding likely to be of interest to clinicians and hospital
administrators.
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OBJECTIVE: To assess the frequency and troublesome-
ness of side-effects of chemotherapy for ovarian cancer as
they affect patients’ physical and social health and 
treatment compliance.
METHOD: A questionnaire was developed based on a
literature review of reactions to chemotherapy and pub-
lished product information on side-effects The question-
naire was pilot tested for time, ease of understanding and
surface validity. Trained clinical interviewers adminis-
tered in-depth face-to-face interviews to 29 women with
ovarian cancer. Participants rated 28 potential side effects
on a 5 point Likert Scale ranging from 0 (Not at all 
troublesome) to 4 (Extremely troublesome), For side-
effects rated at least “slightly troublesome”, a series of
open ended follow-up questions were asked to more fully
understand the response. Chart reviews were conducted
to verify diagnosis and treatment regimens.
RESULTS: Ages ranged from 25 to 78 years (x = 53). The
most frequently reported side-effects (hair loss [n = 25],
general weakness [n = 23], numbness [n = 20], nausea [n
= 19] and infusion reaction [n = 18]) were not perceived
as most troublesome. Means for most troublesome 
side-effects were: infections (x = 3.2), pain in hands and
feet (x = 3.0), constipation (x = 3.0), vomiting (x = 3.0)
and sores in the mouth and throat (x = 2.8). Results indi-
cated side-effects are an extremely common and often
under-treated component of chemotherapy. Many
respondents were bothered that health-care providers
neither gave sufﬁcient warning about the troublesomeness
of speciﬁc side-effects nor provided practical advice on
how symptoms could be ameliorated.
CONCLUSION: The effectiveness of chemotherapy 
regimens as measured through impact on survival as well
as more subjective measures such as quality of life tradi-
tionally do not take into account the signiﬁcant impact
of side-effects on physical and social functioning and
treatment compliance. The nature of side-effects contin-
